
RNA Drug Developer Targets Fresh Funding Channel
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs Key Takeaways: As a pioneer in gene-targeted therapy, Ribo Life has six siRNA candidate drugs …